Morepen Laboratories Limited (IN:MOREPENLAB)
:MOREPENLAB
Want to see IN:MOREPENLAB full AI Analyst Report?
Top Page
Morepen Laboratories Limited
(MOREPENLAB)
Select Model
Select Model
Rating:60Neutral
Price Target:
₹51.00
▲(21.46% Upside)
Action:Reiterated
Date:06/10/26
The score is held back primarily by weak financial quality due to persistently negative free cash flow and higher debt in 2026, despite improved profitability versus 2023. Technicals are supportive with the stock above major moving averages and positive momentum indicators, while valuation is a modest headwind given the higher P/E and low dividend yield.
Positive Factors
Profitability Recovery
The company moved from a 2023 trough to steady positive net income and stronger gross/operating margins in 2024–2026. This durable improvement underpins internal reinvestment capacity and operating resilience, supporting sustainable earnings generation over the medium term.
Negative Factors
Persistent Negative Free Cash Flow
Free cash flow has been negative for three consecutive years, indicating weak cash conversion of earnings. Persistent FCF deficits constrain the firm's ability to self-fund capex, pay down debt, or return cash to shareholders, raising structural financing and liquidity risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Recovery
The company moved from a 2023 trough to steady positive net income and stronger gross/operating margins in 2024–2026. This durable improvement underpins internal reinvestment capacity and operating resilience, supporting sustainable earnings generation over the medium term.
Read all positive factors
Morepen Laboratories Limited (MOREPENLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹27.96B
Dividend Yield0.49%
Average Volume (3M)88.30K
Price to Earnings (P/E)30.2
Beta (1Y)1.81
Revenue Growth-0.32%
EPS Growth-22.18%
CountryIN
Employees2,152
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.79
Shares Outstanding547,953,700
10 Day Avg. Volume126,704
30 Day Avg. Volume88,304
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)1.64
Price to Sales (P/S)1.13
P/FCF Ratio-14.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Morepen Laboratories Limited Business Overview & Revenue Model
Company Description
Morepen Laboratories Limited is an Indian pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), proprietary and generic pharmaceutical formulations, and...
How the Company Makes Money
Morepen Laboratories makes money primarily by selling pharmaceutical and healthcare products through multiple revenue streams. (1) APIs: It manufactures APIs and sells them in bulk to other pharmaceutical companies that use these ingredients to pr...
Morepen Laboratories Limited Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
68
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.60B | 18.06B | 18.30B | 17.02B | 14.18B | 15.42B |
| Gross Profit | 6.15B | 6.82B | 6.30B | 6.18B | 2.19B | 4.81B |
| EBITDA | 1.69B | 1.73B | 1.92B | 1.73B | 856.66M | 1.57B |
| Net Income | 986.27M | 948.77M | 1.18B | 961.60M | 386.75M | 1.02B |
Balance Sheet | ||||||
| Total Assets | 17.36B | 19.36B | 17.78B | 12.93B | 11.10B | 10.70B |
| Cash, Cash Equivalents and Short-Term Investments | 932.86M | 916.99M | 1.27B | 169.45M | 216.66M | 158.03M |
| Total Debt | 1.58B | 2.08B | 1.05B | 289.99M | 251.64M | 1.33B |
| Total Liabilities | 5.39B | 6.89B | 5.91B | 4.46B | 3.58B | 4.92B |
| Stockholders Equity | 11.96B | 12.46B | 11.56B | 8.47B | 7.53B | 5.79B |
Cash Flow | ||||||
| Free Cash Flow | -247.12M | -1.44B | -919.76M | -79.61M | -1.37B | -1.25B |
| Operating Cash Flow | 158.61M | 162.28M | 320.57M | 733.75M | -911.71M | -577.58M |
| Investing Cash Flow | -516.43M | -1.22B | -3.22B | -833.00M | -465.09M | -316.79M |
| Financing Cash Flow | 444.06M | 1.13B | 3.00B | 52.05M | 1.44B | 663.34M |
Morepen Laboratories Limited Technical Analysis
Positive
41.99
Price Trends
43.87
Positive
41.18
Positive
43.55
Positive
Market Momentum
2.32
Negative
63.50
Neutral
82.35
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MOREPENLAB, the sentiment is Positive. The current price of 41.99 is below the 20-day moving average (MA) of 46.55, below the 50-day MA of 43.87, and below the 200-day MA of 43.55, indicating a bullish trend. The MACD of 2.32 indicates Negative momentum. The RSI at 63.50 is Neutral, neither overbought nor oversold. The STOCH value of 82.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MOREPENLAB.
Morepen Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹24.08B | 7.60 | ― | 2.36% | 8.16% | 2.12% | |
64 Neutral | ₹17.11B | 25.64 | ― | 0.71% | 18.98% | 8.30% | |
60 Neutral | ₹27.96B | 30.24 | ― | 0.49% | -0.32% | -22.18% | |
52 Neutral | ₹27.10B | -334.22 | ― | ― | 6.64% | -177.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ₹24.48B | -50.09 | ― | 0.58% | -7.91% | -153.72% | |
43 Neutral | ₹21.41B | -20.11 | ― | 0.08% | 10.73% | -31.79% |
* Healthcare Sector Average
IN:MOREPENLAB
Morepen Laboratories Limited
51.02
-10.22
-16.69%
IN:ALEMBICLTD
Alembic Limited
93.78
-15.33
-14.05%
IN:HIKAL
Hikal Limited
198.50
-159.88
-44.61%
IN:INDOCO
Indoco Remedies Limited
231.90
-52.40
-18.43%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
567.95
37.25
7.02%
IN:WINDLAS
Windlas Biotech Ltd.
808.25
-70.40
-8.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.